Оценка Клинической Эффективности Ингибитора Egfr Эрлотиниба И Полихимиотерапии При Немелкоклеточном Раке Легкого

Key Points

• This research aims to assess the clinical effectiveness of the EGFR inhibitor erlotinib combined with polychemotherapy in non-small cell lung cancer.
• Conducted a randomized trial on non-small cell lung cancer therapies.
• Evaluated the effectiveness of erlotinib and polychemotherapy.
• Analyzed patient outcomes and treatment responses.
• Erlotinib combined with polychemotherapy showed improved clinical outcomes compared to standard treatments.
• Complete response rates and survival benefits were noted, although specific metrics were not provided.